|
|
Phase II Randomized Study of High-Dose Melphalan With Versus Without Targeted Radiotherapy With Yttrium Y 90 Anti-CD66 Monoclonal Antibody BW250/183 in Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma
Alternate Title Basic Trial Information Objectives Entry Criteria Expected Enrollment Outcomes Outline Trial Contact Information Registry Information
Alternate Title
High-Dose Melphalan With or Without Radiolabeled Monoclonal Antibody in Treating Patients With Multiple Myeloma Undergoing an Autologous Stem Cell Transplant
Basic Trial Information
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase II
|
|
|
|
Treatment
|
|
|
|
Active
|
|
|
|
Over 18
|
|
|
|
Other
|
|
|
|
USCTU-ANTI-CD66 USCTU-ANTI-CD66, Eudract-2006-003424-12, EU-20820, NCT00637767
|
|
|
Objectives Primary - To determine the efficacy of high-dose melphalan (200mg/m²) in combination with targeted radiotherapy delivered by yttrium Y 90 anti-CD66 monoclonal antibody BW250/183, in terms of disease response (complete
remission rate and change in serum free light chain level before and after treatment with yttrium Y 90 anti-CD66 monoclonal antibody BW250/183), in patients undergoing autologous hematopoietic stem cell transplantation for multiple
myeloma.
Secondary - To determine the toxicity profile of yttrium Y 90 anti-CD66 monoclonal antibody BW250/183 in the
context of autologous hematopoietic stem cell transplantation.
- To determine the effect of targeted radiotherapy on other parameters of
disease response, in terms of proportion of patients with partial remission,
stable disease, and progressive disease, remission duration (time to
disease progression), and overall survival.
- To determine the effect of targeted radiotherapy on engraftment when used in
combination with high-dose melphalan in patients undergoing autologous hematopoietic stem cell transplantation for multiple myeloma.
- To investigate the pharmacokinetic behavior of indium In 111 anti-CD66 monoclonal antibody BW250/183 (used for dosimetry).
- To continue to develop a dosimetry model based on single-photon emission computed tomography (SPECT) and whole body
gamma camera imaging following administration of the radiolabeled anti-CD66 monoclonal antibody (in a subset of patients at the Southampton site only).
- To assess the proportion of patients who form human anti-murine antibodies
(HAMA) after treatment with targeted radiotherapy in the context of an autologous
hematopoietic stem cell transplantation.
Entry Criteria Disease Characteristics:
- Histologically or cytologically proven multiple myeloma (MM)
- Scheduled to undergo autologous hematopoietic stem cell transplantation (HSCT) as consolidation treatment for MM
- Must have sufficient CD34-positive stem cells
(≥ 4 x 106 cells per kg body weight) in cryo-storage for two autologous HSCTs
- In partial remission (PR) after prior chemotherapy but before priming therapy for stem cell mobilization
- Patients in complete remission (CR) after prior chemotherapy are not eligible
- Bone marrow cellularity ≥
20%
Prior/Concurrent Therapy:
- Recovered from prior therapy
- Alopecia or certain grade 1 toxicities allowed
- More than 4 weeks since prior radiotherapy (except for localized pain control), endocrine therapy, or immunotherapy
- More than 4 weeks since prior and no other concurrent chemotherapy for the underlying
hematological condition, except for the following:
- Cyclophosphamide as priming for stem cell
harvest
- Thalidomide
- More than 3 weeks since prior major thoracic and/or abdominal surgery and recovered
- No prior high-dose therapy and autologous HSCT
- Concurrent radiotherapy allowed for the control of bone pain
- The irradiated lesions are not used for response evaluation
- No other concurrent anti-cancer therapy or investigational drugs during transplantation conditioning
Patient Characteristics:
- WHO performance status 0-1
- Life expectancy ≥ 24 weeks
- Hemoglobin ≥ 9.0 g/dL
- Neutrophils ≥ 1,500/mm³
- Platelets ≥ 50,000/mm³
- Serum bilirubin ≤ 1.5 times upper limit of normal (ULN)
- ALT and/or
AST ≤ 2.5 times ULN
- Creatinine clearance ≥ 50 mL/min
- Not pregnant or nursing
- Negative
pregnancy test
- Fertile female patients must use effective contraception for 4 weeks prior to, during, and for 6 months after completion of study treatment
- Fertile male patients must use effective contraception during and for 6 months after completion of study treatment
- Able to cooperate with study treatment
and follow up
- Human anti-mouse antibody (HAMA) negative
- No active uncontrolled infection
- No high-risk non-malignant systemic disease
- No other condition, that in the investigator’s opinion, would make
the patient an unsuitable candidate for the study
- No known HIV or hepatitis B or C seropositivity
- No history of allergy, including an allergy to rodents or rodent proteins
- No history of eczema or asthma
- No history of New York Heart Association
(NYHA) class III or IV cardiac disease
- No congestive heart failure
Expected Enrollment 90Outcomes Primary Outcome(s)Remission status pre- and post-transplantation, specifically the number of patients who achieve complete remission, as measured by the European Blood and Marrow Transplantation Organization
Response Criteria
Secondary Outcome(s)Disease response, as measured by changes in serum free
light chains (in those patients with serum free light chains that are informative) Disease response, including the proportion of patients with partial
remission, stable disease, and progressive disease and remission
duration (time to disease progression) Engraftment quality, as measured by time to recovery of peripheral blood
neutrophils to > 500/mm³ and platelets > 50, 000/mm³ and duration of recovery for
> 180 days post-transplantation Treatment-related mortality Overall survival Toxicity profile of yttrium Y 90 anti-CD66 monoclonal antibody BW250/183 in the
context of autologous stem cell transplantation Pharmacokinetics of indium In 111 anti-CD66 monoclonal antibody BW250/183 as measured by
serial blood samples and serial planar and single-photon emission computed tomography (SPECT) gamma camera imaging of selected organs Development of a dosimetry model based on SPECT
and whole body gamma camera imaging Proportion of patients who form human anti-murine antibodies
(HAMA) after treatment with targeted radiotherapy in the context of an autologous
hematopoietic stem cell transplantation
Outline This is a multicenter study. Patients are stratified according to disease risk group (low risk [beta-2 microglobulin and
C-reactive protein < 6 or either beta-2 microglobulin or C-reactive protein ≥ 6] vs high risk [both beta-2 microglobulin and
C-reactive protein ≥ 6]). Patients are randomized to 1 of 2 treatment arms. - Arm I: Patients receive a dosimetry dose of indium In 111 anti-CD66 monoclonal antibody BW250/183 IV on day 1 and undergo gamma camera imaging and serial blood samples on days 1-5. Patients then receive a therapeutic dose of yttrium Y 90 anti-CD66 monoclonal antibody BW250/183 IV once between days 9 and 16 and high-dose melphalan IV on day 28. Patients then undergo autologous hematopoietic stem cell transplantation (HSCT) on day 30.
- Arm II: Patients receive high-dose melphalan IV on day 1. Patients then undergo autologous HSCT on day 3.
Patients in arm I undergo blood sample collection periodically for pharmacokinetic and pharmacodynamic studies and analysis of human anti-murine antibody (HAMA) status. After completion of study treatment, patients are followed periodically.
Trial Contact Information
Trial Lead Organizations Southampton General Hospital | | | Kim Orchard, MD, Protocol chair | | | | Trial Sites
|
|
|
|
United Kingdom |
|
England |
|
|
Birmingham |
|
| | | | Queen Elizabeth Hospital at University Hospital of Birmingham NHS Trust |
| | Contact Person | |
|
|
London |
|
| | Saint Bartholomew's Hospital |
| | Contact Person | |
|
|
Southampton |
|
| | Southampton General Hospital |
| | Kim Orchard, MD | |
| Email:
kho@soton.ac.uk |
|
Registry Information | | Official Title | | A Randomised Phase II Clinical Trial Using Targeted Radiotherapy delivered by an Yttrium-90 Radio-Labelled Anti-CD66 Monoclonal Antibody with high dose melphalan compared to melphalan alone, prior to Autologous Stem Cell Transplantation for Multiple Myeloma | | Trial Start Date | | 2007-12-12 | | Trial Completion Date | | 2010-12-17 (estimated) | | Registered in ClinicalTrials.gov | | NCT00637767 | | Date Submitted to PDQ | | 2008-02-19 | | Information Last Verified | | 2008-03-30 |
Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol. Back to Top |
|